![Martin Steiner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Martin Steiner
Vorstandsvorsitzender bei SYNIMMUNE GmbH
Aktive Positionen von Martin Steiner
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ImVision Therapeutics, Inc.
![]() ImVision Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImVision Therapeutics, Inc. develops proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. The company was founded on January 28, 2005 and is headquartered in Hanover, Germany. | Direktor/Vorstandsmitglied | - | - |
Präsident | - | - | |
Unternehmenssekretär | - | - | |
Treasurer | - | - | |
SYNIMMUNE GmbH
![]() SYNIMMUNE GmbH Miscellaneous Commercial ServicesCommercial Services Part of VERAXA Biotech GmbH, SYNIMMUNE GmbH is a biotechnology company based in Tuebingen, Germany. The German company is dedicated to developing innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE's lead product candidate is the flt3 specific antibody flysyn, which was recently tested in a first-in-human phase i/ii clinical study in aml patients. The CEOs are Ludger Große-Hovest, Martin Steiner. SYNIMMUNE GmbH was founded in 2010 by Gundram Jung, Hans-Georg Rammensee, Ludger Große-Hovest, Steffen Aulwurm, Andreas Herrmann. SYNIMMUNE was acquired by VERAXA Biotech GmbH on December 29, 2023 for $35.54 million. | Vorstandsvorsitzender | 01.03.2016 | - |
Karriereverlauf von Martin Steiner
Ehemalige bekannte Positionen von Martin Steiner
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ImVisioN Therapeutics AG
![]() ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future. | Direktor/Vorstandsmitglied | 09.03.2011 | 13.02.2014 |
Vorstandsvorsitzender | 01.08.2008 | 13.02.2014 | |
Finanzdirektor/CFO | 21.01.2010 | 13.02.2014 | |
Gründer | 21.01.2010 | 13.02.2014 | |
Apovia AG | Präsident | 01.01.1997 | 01.01.2004 |
Smithkline Beecham Biologicals Immunotherapeutics | Corporate Officer/Principal | 01.01.1997 | 01.01.1997 |
ImVisioN GmbH
![]() ImVisioN GmbH Miscellaneous Commercial ServicesCommercial Services ImVisioN GmbH provides research in intralymphatic immunotherapy. It is a biotechnology company which specializes the use of intralymphatic immunotherapy to develop treatments for major allergies. Its product, IVN201, is a MAT immunotherapeutic that targets cat dander allergy, a common allergy inadequately addressed by available therapeutic interventions. The company was founded in 2005 and is headquartered in Hanover, Germany. | Vorstandsvorsitzender | 01.01.2005 | - |
Finanzdirektor/CFO | 01.01.2005 | - |
Ausbildung von Martin Steiner
University of Vienna | Doctorate Degree |
University of Michigan | Masters Business Admin |
Statistik
International
Deutschland | 5 |
Österreich | 2 |
Vereinigte Staaten | 2 |
Operativ
Chief Executive Officer | 3 |
Director of Finance/CFO | 2 |
Director/Board Member | 2 |
Sektoral
Commercial Services | 4 |
Consumer Services | 3 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 6 |
---|---|
ImVisioN GmbH
![]() ImVisioN GmbH Miscellaneous Commercial ServicesCommercial Services ImVisioN GmbH provides research in intralymphatic immunotherapy. It is a biotechnology company which specializes the use of intralymphatic immunotherapy to develop treatments for major allergies. Its product, IVN201, is a MAT immunotherapeutic that targets cat dander allergy, a common allergy inadequately addressed by available therapeutic interventions. The company was founded in 2005 and is headquartered in Hanover, Germany. | Commercial Services |
ImVisioN Therapeutics AG
![]() ImVisioN Therapeutics AG Miscellaneous Commercial ServicesCommercial Services ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future. | Commercial Services |
Apovia AG | |
Smithkline Beecham Biologicals Immunotherapeutics | |
ImVision Therapeutics, Inc.
![]() ImVision Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ImVision Therapeutics, Inc. develops proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. The company was founded on January 28, 2005 and is headquartered in Hanover, Germany. | Health Technology |
SYNIMMUNE GmbH
![]() SYNIMMUNE GmbH Miscellaneous Commercial ServicesCommercial Services Part of VERAXA Biotech GmbH, SYNIMMUNE GmbH is a biotechnology company based in Tuebingen, Germany. The German company is dedicated to developing innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE's lead product candidate is the flt3 specific antibody flysyn, which was recently tested in a first-in-human phase i/ii clinical study in aml patients. The CEOs are Ludger Große-Hovest, Martin Steiner. SYNIMMUNE GmbH was founded in 2010 by Gundram Jung, Hans-Georg Rammensee, Ludger Große-Hovest, Steffen Aulwurm, Andreas Herrmann. SYNIMMUNE was acquired by VERAXA Biotech GmbH on December 29, 2023 for $35.54 million. | Commercial Services |
- Börse
- Insiders
- Martin Steiner
- Erfahrung